Investor Fact Sheet

Advancing first-in-class, Novel Tumor Target – guided therapies

ADC, T-cell engagers and Radiopharmaceuticals (diagnostic & therapeutic).

Snapshot

- **Stage:** Preclinical oncology; PoC in PDX models; IND-enabling activities underway
- **Target: NPTXR**—**neo**-expressed on solid tumors across >17 solid cancers; NO expression in normal adult tissue; in tumors membrane-bound and internalizing (ideal for ADC treatments)
- **Lead asset: YB-811** dual-payload ADC (MMAF + exatecan; ADR 1:4+4; next-gen linker chemistry)
- **Development strategy:** Sequence to early human signal
    - **ADC IND-ready by Q4 2027; orphan drug application under way (Bladder CA);** plan for first ADC PoC; **EIH Q1/2 2028 DE; Q2/4 2028 Expansion Cohort**
    - **RPT-Dx imaging (IIT possible Q2/2027) → RPT-Tx therapy (Q3/4 2027)**
    - **BiTCE & TriTCE PoC in Preclinic by end 2026; BiTCE IND ready by Q2/2028**
- **IP:** Protected, modality-agnostic perimeter around NPTXR with exclusive global rights

Programs & Near-Term Milestones

- **RPT-Dx / RPT-Tx:** First-in-human imaging & dosimetry through IIT in Germany; then therapeutic dosing; *Next milestone:* Australia HREC/CTN clearances targeted Q3-2027; initial imaging readout Q1-2028
- **BiTCE (YB-820/821):** NPTXR-directed cytotoxic T-cell engagement (aCD3)
  Next milestone: PoC by Q1/2027; IND-ready by Q2-2028
- **TriTCE (YB-880)**: NPTXR-directed cytotoxic T-cell engagement (aCD3 & aCD28)
  Next milestone: PoC by Q1/2027; outlicensing option
- **ADC (YB-811):** Highly selective tumor killing with dual payloads; ADR 1:4+4
  Next milestone: IND-ready Q4-2027; PoC in human expansion readout Q4-2028; collaboration application with Cancer Research UK for Phase I grant support. Lead KOL committed.

Market & Differentiation

- It is the **TARGET** that **matters most**:
  No presence in normal tissues = **no off tumor on target toxicity**; as shown in animal models
- Broad prevalence across GI, GU, Breast and Lung cancers
- **Competitive whitespace:** No clinical programs targeting NPTXR; strong selectivity profile in preclinical panels
- **Commercial potential:** Internal estimates indicate an ADC-addressable TAM >$100B by 2030 across NPTXR+ cancers; initial peak revenue potential ~$10–12B across first lead indications

Team & Partnerships

- Leadership with 20–35 years of experience across discovery, CMC, clinical, and global regulatory
- Strategic collaborations and a protected IP position to accelerate translation from preclinical data to early human signal

Financing

- **Round size:** CHF 15M ($18.5M); $5M soft-circled as matching investment, lead investor secured
- **Valuation guideposts:** TBD after valuation (example: pre: CHF 45M, post: CHF 60M)
- **Use of proceeds:** CMC & IND-enabling studies, IND submissions/starts (ADC), and early human imaging through IIT in Germany
- **Contact**: Partnerships & Investor Relations: **info@ymmuno.bio** • **www.ymmuno.bio**

Disclaimer: This fact sheet is for information only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Forward-looking statements involve risks and uncertainties; actual results may differ materially.